Skip Navigation


Annals of Oncology Advance Access originally published online on July 12, 2005
Annals of Oncology 2005 16(9):1477-1487; doi:10.1093/annonc/mdi265
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/9/1477    most recent
mdi265v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kaiser, P. C.
Right arrow Articles by Aebi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaiser, P. C.
Right arrow Articles by Aebi, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Retinoid receptors in ovarian cancer: expression and prognosis

P. C. Kaiser1,2, M. Körner3, A. Kappeler3 and S. Aebi1,2,*

1 University Hospital Berne, Department of Medical Oncology, Bern 2 University of Bern, Department of Clinical Research, Bern 3 University of Bern, Institute of Pathology, Bern, Switzerland

* Correspondence to: Dr S. Aebi, Department of Medical Oncology, University Hospital Berne, Inselspital PT2C, 3010 Berne, Switzerland. Tel: +41-31-632-4114; Fax: +41-31-382-1237; Email: stefan.aebi{at}insel.ch

Background: Ovarian cancer is frequently lethal despite aggressive multimodal therapy, and new therapies are therefore needed. Retinoids are potential candidate drugs: they prevent the development of ovarian carcinoma and enhance the efficacy of cytotoxic drugs in ovarian cancer cells. At present, little is known about the retinoid receptor expression in ovarian cancer.

Patients and methods: The retinoid receptors comprise two classes, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), each with three subclasses, {alpha}, ß and {gamma}. We investigated the expression of the subtypes RAR{alpha}, RAR{gamma}, RXR{alpha} and RXRß by immunohistochemistry in ovarian cancers of 80 patients, and assessed their prognostic significance. In addition, we quantified the expression of retinoid receptor mRNA using real-time PCR and correlated the results with clinical characteristics.

Results: RAR{alpha} and RXRß were highly expressed in a majority of ovarian cancers, particularly in advanced stages. High expression of RAR{alpha} was an independent negative prognostic factor of survival in addition to FIGO stage, age and p53 accumulation. The mRNA expression of retinoid receptors did not correlate with clinical properties of the tumors.

Conclusions: Retinoic acid receptors are frequently and strongly expressed in epithelial ovarian cancer and may be indicators of an adverse prognosis. This study provides the molecular basis for the therapeutic use of retinoids in ovarian cancer.

Key words: nuclear receptors, ovarian neoplasms, prognostic factors, retinoic acid receptors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
V. T. Todorov, M. Desch, T. Schubert, and A. Kurtz
The Pal3 Promoter Sequence Is Critical for the Regulation of Human Renin Gene Transcription by Peroxisome Proliferator-Activated Receptor-{gamma}
Endocrinology, September 1, 2008; 149(9): 4647 - 4657.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. Colombo, F. Formelli, M. G. Cantu, G. Parma, M. Gasco, A. Argusti, A. Santinelli, R. Montironi, E. Cavadini, L. Baglietto, et al.
A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer.
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1914 - 1919.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.